# A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

> clinical trial · VERIFIED · 2026-07-17

Status: COMPLETED · Sponsor: Astellas Pharma Global Development, Inc. · Condition: Metastatic Urothelial Cancer and Other Malignant Solid Tumors

- Company: Astellas Pharma Global Development, Inc.
- Sector: Metastatic Urothelial Cancer and Other Malignant Solid Tumors
- Primary source: https://clinicaltrials.gov/study/NCT02091999

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.